Prevention of Venous Thromboembolism in the Geriatric Patient

Cardiology Clinics

Volumn 26, Issue 2, 2008, Pages 221-234

  Brotman, Daniel J ^a   Jaffer, Amir K ^b  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN ETEXILATE; DALTEPARIN; DU 176B; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; PRT 054021; RIVAROXABAN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; YM 150;

AGED; ARTHROPLASTY; AUTOPSY; BLEEDING; CARDIOVASCULAR DISEASE; DEEP VEIN THROMBOSIS; DISEASE PREDISPOSITION; ELDERLY CARE; EPIDEMIOLOGICAL DATA; HOSPITAL PATIENT; HUMAN; INFERIOR CAVA VEIN; LUNG EMBOLISM; PHLEBOGRAPHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURGICAL RISK; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; AZETIDINES; BENZIMIDAZOLES; BENZYLAMINES; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POLYSACCHARIDES; PRODRUGS; PYRIDINES; RISK FACTORS; SURGICAL PROCEDURES, ELECTIVE; VENA CAVA FILTERS; VENOUS THROMBOEMBOLISM;

EID: 41749120992     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2007.12.008     Document Type: Review

References (85)

1. National Center for Injury Prevention and Control. Injury Fact Book 2001-2002 (2001), Centers for Disease Control and Prevention, Atlanta (GA)
2. Silverstein M.D., Heit J.A., Mohr D.N., et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158 (1998) 585-593
3. Havig O. Deep vein thrombosis and pulmonary embolism: an autopsy study with multiple regression analysis of possible risk factors. Acta Chir Scand Suppl 478 (1977) 1-20
4. Lindblad B., Eriksson A., and Bergqvist D. Autopsy-verified pulmonary embolism in a surgical department: analysis of the period from 1951 to 1988. Br J Surg 78 (1991) 849-852
5. Hirsh J., and Hoak J. Management of deep vein thrombosis and pulmonary embolism: a statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation 93 (1996) 2212-2245
6. Heit J.A., Melton III L.J., Lohse C.M., et al. Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clin Proc 76 (2001) 1102-1110
7. Anderson Jr. F.A., Wheeler H.B., Goldberg R.J., et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151 (1991) 933-938
8. Graves EJ, Owings MF. 1996 summary: national hospital discharge survey. National Center for Health Statistics. Vital Health Stat Series No. 301. 1998.
9. Stein P.D., Hull R.D., Kayali F., et al. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med 164 (2004) 2260-2265
10. Kniffin Jr. W.D., Baron J.A., Barret J., et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 154 (1994) 861-866
11. Heit J.A., O'Fallon W.M., Petterson T.M., et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med 162 (2002) 1245-1248
12. Geerts W.H., Pineo G.F., Heit J.A., et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 338S-400S
13. Mismetti P., et al. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 88 (2001) 913-930
14. Morgenthaler T.I., and Ryu J.H. Clinical characteristics of fatal pulmonary embolism in a referral hospital. Mayo Clin Proc 70 (1995) 417-424
15. Attems J., et al. The clinical diagnostic accuracy rate regarding the immediate cause of death in a hospitalized geriatric population; an autopsy study of 1594 patients. Wien Med Wochenschr 154 (2004) 159-162
16. Morpurgo M., and Schmid C. The spectrum of pulmonary embolism: clinicopathologic correlations. Chest 107 1 Suppl (1995) 18S-20S
17. Leizorovicz A., et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110 (2004) 874-879
18. Brotman D.J., et al. Virchow's triad revisited. South Med J 97 (2004) 213-214
19. Virchow R. Gesammelte abhandlungen zur wissenschaftlichen medicin [Thrombosis and emboli] (1998), Science History Publications/USA, Canton (MA) [Matzdorff AC, Bell WR, Trans.; original text published 1856.]
20. Jaffer A.K., Barsoum W., Krebs V., et al. Duration of anesthesia and venous thromboembolism following hip and knee arthroplasty. Mayo Clinic Proceedings 80 (2005) 732-738
21. Edmonds M.J., Crichton T.J., Runciman W.B., et al. Evidence-based risk factors for postoperative deep vein thrombosis. ANZ J Surg 74 (2004) 1082-1097
22. Goldhaber S.Z., and Tapson V.F. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol 93 (2004) 259-262
23. Kahn S.R., et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 119 2 (2007) 145-155
24. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 188S-203S
25. Cade J.F., Andrews J.T., and Stubbs A.E. Comparison of sodium and calcium heparin in prevention of venous thromboembolism. Aust N Z J Med 12 (1982) 501-504
26. Gallus A.S., Hirsch J., Tuttle R.J., et al. Small subcutaneous doses of heparin in prevention of venous thrombosis. N Engl J Med 288 (1973) 545-551
27. Belch J.J., Lowe G.D., Ward A.G., et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 26 (1981) 115-117
28. Samama M.M., Cohen A.T., Darmon J.Y., et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 341 (1999) 793-800
29. McGarry L.J., Thompson D., Weinstein M.C., et al. Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care 10 (2004) 632-642
30. Hillbom M., Erila T., Sotaniemi K., et al. Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand 106 (2002) 84-92
31. Kleber F.X., Witt C., Vogel G., et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145 (2003) 614-621
32. Bergmann J.F., and Neuhart E. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost 76 (1996) 529-534
33. Harenberg J, SU, Flosbach CW, et al. Enoxaparin is superior to unfractionated heparin in the prevention of thromboembolic events in medical inpatients at increased thromboembolic risk. Blood 1999;94:399a.
34. Lechler E., Schramm W., and Flosbach C.W. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis 26 Suppl 2 (1996) 49-56
35. Harenberg J., Roebruck P., and Heene D.L. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. The Heparin Study in Internal Medicine Group. Haemostasis 26 (1996) 127-139
36. Cohen A.T., et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332 7537 (2006) 325-329
37. Freedman K.B., Brookenthal K.R., Fitzgerald Jr. R.H., et al. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am 82 (2000) 929-938
38. Amaragiri S.V., and Lees T.A. Elastic compression stockings for prevention of deep vein thrombosis. Cochrane Database Syst Rev 3 (2000) CD001484
39. Handoll H.H., Farrar M.J., McBirnie J., et al. Heparin, low molecular weight heparin and physical methods for preventing deep vein thrombosis and pulmonary embolism following surgery for hip fractures. Cochrane Database Syst Rev 4 (2002) CD000305
40. Mazzone C., Chiodo G.F., Sandercock P., et al. Physical methods for preventing deep vein thrombosis in stroke. Cochrane Database Syst Rev 4 (2004) CD001922
41. Santori F.S., Vitullo A., Stopponi M., et al. Prophylaxis against deep-vein thrombosis in total hip replacement: comparison of heparin and foot impulse pump. J Bone Joint Surg Br 76 (1994) 579-583
42. Norgren L., Toksvig-Larsen S., Magyar G., et al. Prevention of deep vein thrombosis in knee arthroplasty: preliminary results from a randomized controlled study of low molecular weight heparin vs foot pump compression. Int Angiol 17 (1998) 93-96
43. Wille-Jorgensen P., Rusmussen M.S., Andersen B.R., et al. Heparins and mechanical methods for thromboprophylaxis in colorectal surgery. Cochrane Database Syst Rev 4 (2003) CD001217
44. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin. Pulmonary Embolism Prevention (PEP) trial. Lancet 355 (2000) 1295-1302
45. Gent M., Hirsh J., Ginsberg J.S., et al. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture. Circulation 93 (1996) 80-84
46. Collins R., Scrimgeour A., Yusuf S., et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 318 (1988) 1162-1173
47. Colwell Jr. C.W. Recent advances in the use of low molecular weight heparins as prophylaxis for deep vein thrombosis. Orthopedics 17 (1994) 5-7
48. Colwell Jr. C.W., Spiro T.E., Trowbridge A.A., et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement: a clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am 76 (1994) 3-14
49. Planes A., Vochelle N., Mazas F., et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 60 (1988) 407-410
50. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement: a randomized trial. The German Hip Arthroplasty Trial (GHAT) Group. Arch Orthop Trauma Surg 111 (1992) 110-120
51. Mesko J.W., Brand R.A., Iorio R., et al. Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership. J Arthroplasty 16 (2001) 679-688
52. Mismetti P., Laporte S., Zufferey P., et al. Prevention of venous thromboembolism in orthopedic surgery with vitamin K antagonists: a meta-analysis. J Thromb Haemost 2 (2004) 1058-1070
53. White R.H., Romano P.S., Zhou H., et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 158 (1998) 1525-1531
54. Brotman D.J., Jaffer A.K., Hurbanek J.G., et al. Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty. Thromb Haemost 92 (2004) 1012-1017
55. Botteman M.F., Caprini J., Stephens J.M., et al. Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United States. Clin Ther 24 (2002) 1960-1986 [discussion; 1938]
56. Hawkins D.W., Langley P.C., and Krueger K.P. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery. Clin Ther 20 (1998) 182-195
57. Garcia-Zozaya I. Warfarin vs enoxaparin for deep venous thrombosis prophylaxis after total hip and total knee arthroplasty: a cost comparison. J Ky Med Assoc 96 (1998) 143-148
58. Turpie A.G., Bauer K.A., Eriksson B.I., et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. [comment]. Arch Intern Med 162 (2002) 1833-1840
59. Eriksson B.I., Bauer K.A., Lassen M.R., et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345 (2001) 1298-1304
60. Eriksson B.I., and Lassen M.R. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 163 (2003) 1337-1342
61. Weitz J.I., Hirsh J., and Samama M.M. New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 265S-286S
62. Eriksson B.I., Bergqvist D., Kalebo P., et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 360 (2002) 1441-1447
63. Eriksson B.I., Arfrwidsson A.C., Frison L., et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost 87 (2002) 231-237
64. Eriksson B.I., Agnelli B., Cohen A.T., et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 1 (2003) 2490-2496
65. Eriksson B.I., Agnelli B., Cohen A.T., et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 89 (2003) 288-296
66. Francis C.W., Berkowitz S.D., Comp P.C., et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 349 (2003) 1703-1712
67. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate is effective and safe for the extended prevention of venous thromboembolism following total hip replacement. Abstract presented at XXIst Congress of the International Society on Thrombosis and Haemostasis in Geneva, Switzerland, July 2007.
68. Caprini JA, Hwang E, Hantel S, et al. The oral direct thrombin inhibitor dabigatran etexilate is effective and safe for prevention of major venous thromboembolism following orthopaedic surgery. Abstract presented at XXIst Congress of the International Society on Thrombosis and Haemostasis in Geneva, Switzerland, July 2007.
69. Strebel N., Prins M., Agnelli G., et al. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery?. Arch Intern Med 162 (2002) 1451-1456
70. Horlocker T.T., Wedel D.J., Benzon H., et al. Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation). Reg Anesth Pain Med 28 (2003) 172-197
71. Beyth R.J., Quinn L.M., and Landefeld C.S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 105 (1998) 91-99
72. Landefeld C.S., McGuire III E., and Rosenblatt M.W. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 89 (1990) 569-578
73. Campbell N.R., Hull R.D., Brant R., et al. Aging and heparin-related bleeding. Arch Intern Med 156 (1996) 857-860
74. Wells P.S., Forgie M.A., Simms M., et al. The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med 163 (2003) 917-920
75. Decousus H., Leizorovicz A., Parent F., et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. [see comment]. N Engl J Med 338 (1998) 409-415
76. Streiff M.B. Vena caval filters: a review for intensive care specialists. J Intensive Care Med 18 (2003) 59-79
77. Alexander J.J., Yuhas J.P., and Piotrowski J.J. Is the increasing use of prophylactic percutaneous IVC filters justified?. Am J Surg 168 (1994) 102-106
78. Walsh D.B., Birkmeyer J.D., Barrett J.A., et al. Use of inferior vena cava filters in the Medicare population. Ann Vasc Surg 9 (1995) 483-487
79. Offner P.J., Hawkes A., Madayag R., et al. The role of temporary inferior vena cava filters in critically ill surgical patients. Arch Surg 138 (2003) 591-594 [discussion: 594-5]
80. Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: the EXCLAIM study. Presented at: International Society on Thrombosis and Haemostasis XXIst Congress; July 6-12, 2007; Geneva, Switzerland.
81. Davidson B.L., Berkowitz S.D., Lotke P.A., et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Ann Intern Med 137 (2002) 648-655
82. Eikelboom J.W., Quinlan D.J., and Douketis J.D. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358 (2001) 9-15
83. Kearon C. Duration of therapy for acute venous thromboembolism. Clin Chest Med 24 (2003) 63-72
84. Bergqvist D., Agnelli G., Cohen A.T., et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 346 (2002) 975-980
85. Rasmussen M.S. Preventing thromboembolic complications in cancer patients after surgery: a role for prolonged thromboprophylaxis. Cancer Treat Rev 28 (2002) 141-144